Physician profile
Robert A Martin
NPI 1841297181
$3,790.92
in general payments reported to CMS, 2019-2025
31 companies · $593 in 2025
The $593 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $77.50 · 2021: $497 · 2022: $750 · 2023: $884 · 2024: $693 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $488.13 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $430.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $332.48 | 2019-2025 | |
| Lilly USA, LLC | $322.18 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $301.88 | 2019-2024 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.28 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $260.51 | 2019-2025 | Rexulti, Abilify Maintena |
| Daiichi Sankyo INC. | $143.05 | 2021-2024 | Injectafer |
| Abbott Laboratories | $136.09 | 2021-2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $135.84 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $135.21 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $125.62 | 2022-2024 | Ingrezza |
| Dexcom, INC. | $79.71 | 2022-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.66 | 2025 | Caplyta |
| Pharmacosmos Therapeutics INC. | $68.13 | 2025 | Monoferric |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59.39 | 2022-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $51.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.75 | 2019-2021 | |
| Gilead Sciences, INC. | $39.24 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.94 | 2023 | |
| Abbvie INC. | $37.67 | 2021 | |
| Lundbeck LLC | $37.03 | 2024-2025 | Rexulti |
| Eisai INC. | $34.43 | 2021-2022 | |
| Organon LLC | $25.24 | 2023-2025 | Jada System, Nexplanon |
| Astellas Pharma US INC | $18.94 | 2023 | Veozah |
| Medtronic, INC. | $16.30 | 2021 | |
| Glaxosmithkline, LLC. | $15.23 | 2021 | |
| Exact Sciences Corporation | $14.93 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $14.58 | 2019 | |
| Viatris Specialty LLC | $14.02 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $3.99 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.